Back to search results

GLP-1 Medications and Behavioral Programs for Weight and Metabolic Health

This study, called FLOURISH and THRIVE, is looking at how well Noom's digital health programs, including those with medications like semaglutide and tirzepatide, help with weight loss and improve health markers. Researchers want to see how these programs affect your body weight, blood sugar levels (fasting glucose and HbA1c), and other health indicators. You might be eligible if you are between 18 and 64 years old, speak English, can walk on your own, and are willing to stay on your current program for 12 months. The study is currently unclear on its recruitment status.

Study design
This is an observational study with a planned enrollment of 2310 participants, divided into two main parts: FLOURISH (6 groups) and THRIVE (2 groups).
What's involved
You would complete monthly surveys, provide blood samples for biomarker collection, use a connected scale for weigh-ins, and perform in-app biometric assessments.
Compensation
Not stated in the trial record.
Follow-up
You would be followed for 12 months, with additional follow-ups at 18 and 24 months if you are in a GLP-1 medication group.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07588984

GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study

Not Yet Recruiting
Not specifiedAges 18–64Observational
Noom Inc.
~2,310 participants
Updated 2026-05-15 on ClinicalTrials.gov
What's tested:Noom WeightFree TierEducation-only controlSemaglutideTirzepatideMicrodose semaglutide

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Body Weight
Measured over Monthly, Baseline through Month 12 (and Months 18 & 24 for FLOURISH GLP-1 arms)
+8 more outcomes measured

Conditions

Obesity & Overweight
Weight Loss
Preventative Health
Body Weight
Cardiovascular Disease Risk Factor

Explore related trials

ObesityOverweight

Where it's being run

1 sites across 1 states
New Jersey1

Study leadership

  • Erin C Owen, PhD, MPH · PRINCIPAL_INVESTIGATOR · Noom Inc.

Who to contact

Erin C Owen, PhD, MPH
[email protected]
(929)-644-7193
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Speaks English
Community-dwelling, community-living status
Able to ambulate independently, with or without aids or devices
Unless medically indicated, willingness to stay on current program for 12 months and participate in all study activities
Provides informed consent for study participation
Commitment and willingness to participate, as assessed by completion of decisional balance exercise
Program-specific eligibility:
Medication arms only: Meets standard of care program enrollment criteria for GLP-1 medication. Did not add other products or programs to Noom subscription.
Noom Weight only: Individual who is not interested in medication
Education-only Control Group: Individual who is interested in weight loss who is not currently enrolled in a structured weight loss program or medication program and does not intend to for the duration of the study Free Tier only: Willingness to use Free Tier

Exclusion

Study screener completed more than 11 days after Noom program enrollment if participating in a Noom program (GLP-1 programs, Noom Weight, and Free Tier)
GLP-1 use in the last 24 weeks (prior to Noom program enrollment if in GLP-1 arm)
Female who is pregnant, breast-feeding, or intends to become pregnant during the 12-month program
Previous or planned (during the 12-month study) bariatric surgery
Active eating disorder
Active cancer
Type 1 diabetes or current Insulin use
Currently taking a medication known to cause weight gain (e.g., antipsychotics, antidepressants, diabetes medication, or corticosteroids)
Depression screen results in a PHQ-8 score of 20 or greater.
GLP-1 agonist use is contraindicated (per program criteria) in members with:
Personal or family history of medullary thyroid cancer
Personal or family history of Multiple Endocrine Neoplasia Type 2 (MEN2)
Personal history of Pancreatitis

What this trial measures

  • Change in Body WeightMonthly, Baseline through Month 12 (and Months 18 & 24 for FLOURISH GLP-1 arms)

    Change from baseline in body weight (kg/lbs) measured via connected scale.

  • Change in fasting glucoseBaseline, Month 2, Month 4, Month 8, Month 12

    Change from baseline in fasting glucose (milligrams per deciliter (mg/dL)) measured via Tasso+ capillary blood collection device.

  • Change in HbA1cBaseline, Month 2, Month 4, Month 8, Month 12

    Change from baseline in HbA1c (mmol/mol and percentage) measured via Tasso+ capillary blood collection device.

  • Change in LDL cholesterolBaseline, Month 2, Month 4, Month 8, Month 12

    Change from baseline in LDL cholesterol (milligrams per deciliter (mg/dL)) measured via Tasso+ capillary blood collection device.

  • Change in HDL cholesterolBaseline, Month 2, Month 4, Month 8, Month 12

    Change from baseline in HDL cholesterol (milligrams per deciliter (mg/dL)) measured via Tasso+ capillary blood collection device.

  • Change in total cholesterolBaseline, Month 2, Month 4, Month 8, Month 12

    Change from baseline in total cholesterol (milligrams per deciliter (mg/dL)) measured via Tasso+ capillary blood collection device.

  • Change in triglyceridesBaseline, Month 2, Month 4, Month 8, Month 12

    Change from baseline in triglycerides (milligrams per deciliter (mg/dL)) measured via Tasso+ capillary blood collection device.

  • Change in Body CompositionMonthly, Baseline through Month 12 ((and Months 18 & 24 for FLOURISH GLP-1 arms)

    Change from baseline in estimated body composition metrics (lean mass, fat mass percentage) as measured via in-app BodyScan feature.

  • GLP-1 Side Effect ProfileBaseline (pre-treatment), Monthly through Month 12

    Number, severity, and tolerance of GLP-1 medication-related side effects (nausea, vomiting, diarrhea, constipation, headache, fatigue, injection site reactions) assessed via monthly self-report. Applicable to GLP-1 arms only.